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Abstract
Background: Chemoprevention offers a promising strategy for prevention of malaria in African children. However, the
optimal chemoprevention drug and dosing strategy is unclear in areas of year-round transmission and resistance to many
antimalarial drugs. To compare three available regimens, we conducted an open-label randomized controlled trial of
chemoprevention in Ugandan children.
Methods and Findings: This study was conducted between June 28, 2010, and September 25, 2013. 400 infants were
enrolled and 393 randomized at 6 mo of age to no chemoprevention, monthly sulfadoxine-pyrimethamine (SP), daily
trimethoprim-sulfamethoxazole (TS), or monthly dihydroartemisinin-piperaquine (DP). Study drugs were administered at
home without supervision. Piperaquine (PQ) levels were used as a measure of compliance in the DP arm. Participants were
given insecticide-treated bednets, and caregivers were encouraged to bring their child to a study clinic whenever they were
ill. Chemoprevention was stopped at 24 mo of age, and participants followed-up an additional year. Primary outcome was
the incidence of malaria during the intervention period. During the intervention, the incidence of malaria in the no
chemoprevention arm was 6.95 episodes per person-year at risk. Protective efficacy was 58% (95% CI, 45%–67%, p,0.001)
for DP, 28% (95% CI, 7%–44%, p= 0.01) for TS, and 7% for SP (95% CI, 219% to 28%, p= 0.57). PQ levels were below the
detection limit 52% of the time when malaria was diagnosed in the DP arm, suggesting non-adherence. There were no
differences between the study arms in the incidence of serious adverse events during the intervention and the incidence of
malaria during the 1-y period after the intervention was stopped.
Conclusions: For preventing malaria in children living in an area of high transmission intensity, monthly DP was the most
efficacious and safe, although adherence may pose a problem. Monthly SP and daily TS may not be appropriate in areas
with high transmission intensity and frequent resistance to antifolates.
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Introduction
Malaria remains one of the most important infectious diseases
worldwide, with an estimated 219 million cases and 660,000
deaths in 2010 [1]. Approximately 90% of deaths occurred in
Africa, with children under 5 y of age the most severely affected
[1]. Malaria control for African children largely relies on the use of
insecticide-treated bednets (ITNs), indoor residual spraying of
insecticide, and case management with artemisinin-based combi-
nation therapy (ACT). However, there are limitations to the
effectiveness of all of these interventions, and new strategies are
urgently needed to reduce the burden of malaria for those at
greatest risk.
The use of antimalarial drugs for the prevention of malaria in
children at high risk has recently received widespread attention.
Most studied is intermittent preventive therapy in infants (IPTi)
with sulfadoxine-pyrimethamine (SP) at the time of routine
vaccinations. A pooled analysis of six randomized controlled trials
reported that IPTi with SP was safe and was associated with a 30%
(95% CI, 19%–39%) protective efficacy against malaria in the first
year of life [2]. Daily chemoprophylaxis with another antifolate
combination, trimethoprim-sulfamethoxazole (TS), has also been
shown to be effective for the prevention of malaria in HIV-infected
and -uninfected children, with protective efficacies of 39% (95%
CI, 19%–54%) and 99% (95% CI, 96%–100%) in randomized
trials from Uganda and Mali, respectively [3,4]. In parts of west
Africa where transmission is largely restricted to a few months
each year and antifolate resistance is uncommon, seasonal malaria
chemoprevention (SMC) at monthly intervals during the trans-
mission season has been highly effective. In a systematic review
and meta-analysis of 12 studies, SMC with regimens including SP
primarily combined with amodiaquine (AQ) provided an overall
protective efficacy of 82% (95% CI, 75%–87%) against malaria
and 57% (95% CI, 24%–76%) against all-cause mortality [5].
However, alternative drugs and/or approaches may be needed in
areas where the prevalence of resistance to antifolate drugs is high
or malaria transmission occurs throughout the year.
To compare available drug regimens for the prevention of
malaria in an area with high antifolate resistance and intense,
year-round transmission, we conducted a randomized controlled
trial evaluating three regimens for the prevention of malaria in
young children in Tororo, Uganda: monthly SP, daily TS, and
monthly dihydroartemisinin-piperaquine (DP), an ACT that is
especially attractive because of its excellent treatment efficacy and
prolonged post-treatment prophylactic effect [6]. All study
participants were given an ITN at enrollment, and the primary
objective was to compare the incidence of malaria between the
three chemoprevention arms and a control group that received no
chemoprevention.
Methods
Ethics Statement
Ethical approval was obtained from the Uganda National
Council for Science and Technology, the Makerere University
School of Medicine Research and Ethics Committee, and the
University of California, San Francisco, Committee on Human
Research.
Study Design, Site, and Population
We performed a randomized, controlled, open-label trial from
June 28, 2010, to September 25, 2013, comparing the efficacy and
safety of three regimens versus no therapy for the prevention of
malaria in Tororo District, eastern Uganda, an area with intense
year-round malaria transmission and an entomological inoculation
rate estimated at 562 infectious bites per person-year in 2002 [7].
Convenience sampling was used to enroll a cohort of 400 infants
of 4–5 mo of age from the Tororo District Hospital Maternal and
Child Health Clinic between June 28, 2010, and February 24,
2011. Eligibility criteria included the following: (1) born to HIV-
uninfected mothers, (2) residency within 30 km of the study clinic
with no intention of moving outside the study area, (3) agreement
to come to the study clinic for any illness and to avoid medications
outside the study protocol, (4) provision of informed consent by
parent/guardian, (5) no history of allergy or sensitivity to any study
drugs, (6) absence of active medical problem requiring in-patient
evaluation or chronic medical conditions requiring frequent
attention, and (7) absence of clinically significant electrocardio-
gram (ECG) abnormalities, family history of long QT syndrome,
and current use of drugs that prolong the QTc interval. Only one
eligible child was enrolled per household, and at enrollment each
household was given two long-lasting ITNs. The purposes and
benefits of sleeping under the ITNs were explained to the primary
caregivers, and ITN use was encouraged throughout the study.
Study Drugs and Treatment Allocation
A randomization list using permuted variable-sized blocks of 4,
8, and 12 was computer generated by a member of the study not
directly involved in patient care. Study participants were
randomized to their assigned treatment group at 6 mo of age
using premade, consecutively numbered, sealed envelopes. Treat-
ment allocation was performed by nurses not involved with patient
care. Study drugs were dosed as follows: TS (co-trimoxazole,
Kampala Pharmaceutical Industries, Uganda), single dose once
daily; SP (Kamsidar, Kampala Pharmaceutical Industries,
Uganda), single dose each month; and DP (Duo-Cotexin, Beijing
Holley-Cotec Pharmaceuticals, China), once daily for three
consecutive days each month; each drug was provided for
administration at home according to weight-based guidelines. All
study drugs were in compliance with local Good Manufacturing
Practices. At the time of treatment allocation, parents/guardians
were given a 2-mo supply of drugs and a diary with dates for
dosing and check-offs to indicate administration. Parents/guard-
ians were instructed to re-administer drugs if children vomited
within 30 min of administration and to bring children to the clinic
if they vomited again. During each visit to the study clinic, parent/
guardians were questioned about study drug use and resupplied to
maintain a 2-mo supply.
Study Procedures
Participants received all of their medical care at a designated
study clinic open every day. Parents/guardians were encouraged
to bring their children to the clinic any time they were ill. Children
who presented with a documented fever (tympanic temperature $
38.0uC) or history of fever in the previous 24 h had blood obtained
by finger prick for a thick blood smear. If the smear was positive,
the patient was diagnosed with malaria, and a complete blood
count and thin blood smear for parasite speciation were
performed. Episodes of uncomplicated malaria were treated with
artemether-lumefantrine (AL), the recommended first-line treat-
ment in Uganda. AL was administered twice a day for 3 d, with
the first daily dose given directly observed in the clinic and the
second daily dose administered at home. Episodes of complicated
malaria (severe malaria or danger signs) [8] or treatment failures
occurring within 14 d of prior therapy were treated with quinine.
Routine evaluations, including thick blood smears and assessment
of use of ITNs and adherence to study drugs, were done monthly.
Complete blood count and glucose and alanine aminotransferase
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levels were assessed every 4 mo. ECGs were performed monthly in
every fifth study participant randomized to DP if they could be
brought to the clinic on the day they took their third dose in a
given month. Adverse events were assessed and graded according
to severity (mild, moderate, severe, life-threatening) using
standardized criteria at every clinic visit. A serious adverse event
was defined as any adverse experience that resulted in death, life-
threatening experience, participant hospitalization, persistent or
significant disability or incapacity, or specific medical or surgical
intervention to prevent serious outcome. Diagnosis of incident
episodes of non-malarial illnesses, including diarrheal illnesses and
respiratory tract infections, were based on a prespecified list of
diagnostic criteria developed by the study team. Medications with
antimalarial activity were avoided for the treatment of non-
malarial illnesses when possible. Antihelmintics, iron sulfate, and
vitamin A were prescribed following Integrated Management of
Childhood Illnesses guidelines.
Chemoprevention was stopped at 24 mo of age, and study
participants were followed-up one additional year until they
reached 36 mo of age. Study participants were prematurely
withdrawn from the study for (1) movement out of the study area,
(2) failure to be seen in the study clinic for .60 consecutive days,
(3) withdrawal of informed consent, or (4) inability to comply with
the study schedule and procedures.
Laboratory Procedures
Thick and thin blood smears were stained with 2% Giemsa for
30 min. Parasite density was estimated by counting the number of
asexual parasites per 200 white blood cells and assuming a white
blood cell count of 8,000 per microliter. A smear was deemed
negative if no parasites were seen in 100 high-powered fields.
Microscopy quality control included rereading all blood smears
and resolution of any discrepancies by a third microscopist.
Piperaquine (PQ) drug levels were measured from capillary
blood collected on filter paper on the day malaria was diagnosed
among study participants randomized to monthly DP. Levels of
drugs from the other treatment arms were not measured because
of resource constraints. Briefly, dried blood spots were punched
from Whatman cards and extracted with 100 ml of a 1:1 mixture of
20% trichloroacetic acid and acetonitrile. Nevirapine-d5 was used
as the internal standard because its retention time (1.17 min) was
the closest to that of PQ (1.21 min) among several compounds
screened. The extract (10 ml) was directly injected onto a liquid
chromatography–tandem mass spectrometry system API5000.
Separation was achieved on a PFP column (2.1650 mm, 3 mm)
eluted with aqueous 0.14% trifluoroacetic acid, 10 mM ammoni-
um formate, and acetonitrile. The PQ assay demonstrated a lower
limit of quantitation of 10 ng/ml with a calibration range of 10–
100 ng/ml. Inter- and intra-day accuracy ranged from 97.6% to
106% and from 93.9% to 112%, respectively, and inter- and intra-
day variation ranged from 7.4% to 12% and from 4.4% to 14%,
respectively.
Statistical Analysis
This study was part of a protocol that included two randomized
controlled trials to evaluate the protective efficacy and safety of
antimalarial chemopreventive regimens in distinct populations of
HIV-unexposed (HIV-uninfected children born to HIV-uninfect-
ed mothers) and HIV-exposed (HIV-uninfected children born to
HIV-infected mothers) children. Here we only present the findings
from the trial conducted in HIV-unexposed children. The other
results will be presented elsewhere. The study presented here was
designed to test the hypotheses that chemoprevention lowers the
incidence of malaria compared to no chemoprevention, and that
the optimal chemoprevention regimen is DP. The sample size was
calculated to detect at least a 32% lower incidence of malaria in
the DP arm compared to that in the TS arm. We assumed that the
incidence of malaria would be 1.85 episodes per person-year with
TS chemoprevention based on a prior cohort study in the same
area [3], and thus we calculated that we would need to enroll 100
participants in each arm to detect our targeted protective efficacy
with 80% power at 95% significance (two-sided), allowing for 10%
loss to follow-up.
Data were double-entered and verified in Microsoft Access, and
statistical analyses were performed using Stata, version 12
(StataCorp). All analyses used a modified intention-to-treat
approach, including all study participants randomized to therapy
and including all follow-up time until the study participant reached
a study end point or early study termination, regardless of whether
the intervention was stopped due to an adverse event. Descriptive
statistics included means and standard deviations for continuous
variables and proportions for categorical variables. The primary
outcome was the incidence of malaria, defined as the number of
incident episodes per time at risk, during the period the
intervention was given (6–24 mo of age). Treatments within 14
d of a prior episode were not considered incident events. Time at
risk was from the day following the initiation of study drugs to the
last day of observation, minus 14 d after each treatment for
malaria. Secondary outcomes included the incidence of compli-
cated malaria, all-cause hospitalizations, diarrheal illnesses,
respiratory tract infections, and serious adverse events or adverse
events of moderate or greater severity (grade 3–4); the prevalence
of moderate–severe anemia (hemoglobin,8 gm/dl) measured at
the time of each episode of malaria and at the time of routine
testing done every 4 mo; and the prevalence of parasitemia and
gametocytemia measured at the time of monthly routine blood
smears in study participants who were asymptomatic. Response to
antimalarial therapy among children diagnosed with symptomatic
malaria was also a secondary outcome, and will be presented
separately. To assess the impact of chemoprevention on the
development of naturally acquired immunity, the incidence of
malaria, complicated malaria, and hospitalizations was compared
between treatment arms for children 24–36 mo of age after the
intervention was stopped.
Incidence outcomes were compared using a negative binomial
regression model, and prevalence outcomes and measure of use of
ITNs at the time of monthly assessments were compared using
generalized estimating equations with adjustment for repeated
measures in the same study participant. For all analyses, only the
assigned study arm was included as a covariate, with the exception
of a multivariable analysis performed for the primary outcome of
malaria incidence, which also included other covariates that were
thought to be potential independent risk factors for malaria.
Measures of association were expressed as protective efficacy
(PE= 1 minus the incident rate ratio or prevalence ratio) during
the intervention and incident rate ratios after the intervention was
stopped. p,0.05 was considered statistically significant.
Results
400 infants were enrolled, 393 (98%) of whom reached 6 mo of
age and were randomized to one of the four study arms (Figure 1).
Baseline characteristics at enrollment were similar across all study
arms (Table 1). At enrollment 24% of study participants had a
positive thick blood smear (all asymptomatic parasitemia). Among
the 393 infants randomized to therapy, 352 (89.6%) were followed
up to 24 mo of age, and 340 (86.5%) were followed up to 36 mo of
age, representing 93.6% and 91.4% of potential follow-up time,
Malaria Chemoprevention in a High Transmission Area
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respectively (Figure 1). All families were given two ITNs at
enrollment; 98.5% of study participants reported sleeping under
an ITN at monthly assessments, without significant differences
between study arms (p=0.36).
During the intervention, the incidence of malaria in the no
chemoprevention group was 6.95 episodes per person-year at risk
(Table 2). Compared to the no chemoprevention group, monthly
SP provided no significant protection against malaria (PE= 7%,
95% CI, 219% to 28%, p=0.57), daily TS was moderately
protective (PE= 28%, 95% CI, 7%–44%, p=0.01), and monthly
DP provided the greatest protection (PE= 58%, 95% CI, 45%–
67%, p,0.001). Results were very similar when using multivar-
iable analyses to adjust for household wealth index, level of
education of primary caregiver, whether the child was parasitemic
at enrollment, residence in village or town, nutritional status at
enrollment (defined as length-for-age z-score), and type of
materials used for house construction (Table 3). In all four arms
the incidence of malaria increased with age (Figure 2), and the
protective efficacies of all three interventions were greater for
children at age 6–11 mo than at age 12–24 mo (Table 2). When
compared to daily TS, the protective efficacy of monthly DP was
41% (95% CI, 21%–56%, p,0.001).
The proportions of assigned doses reportedly administered at
home based on diaries completed by primary caregivers were
99.2% for SP, 98.5% for TS, and 99.2% for DP. To further
explore adherence among study participants randomized to
monthly DP, PQ blood concentrations were measured at the time
of each episode of malaria. Among 366 episodes, 348 samples were
available for analysis. For ten episodes, PQ levels were .100 ng/
ml, and the primary caregivers reported giving the DP within the
prior 24 h, suggesting the coincidental onset of malaria just before
the scheduled time for monthly DP dosing. For the remaining 338
samples there was no relationship between PQ levels and the
number of days since the last dose of DP was reported given
(Figure 3). In addition, PQ levels were below the level of detection
(,10 ng/ml) on the day malaria was diagnosed in 52% of
episodes, suggesting that a complete dose of DP was not
administered in the previous month [9,10]. Thus, despite caregiver
reports to the contrary, our results suggest frequent non-adherence
with study dosing schedules.
During the intervention, a total of 2,487 treatments were given
for malaria (96.7% Plasmodium falciparum), including 2,460 for
incident episodes and 27 for episodes occurring within 14 d of a
prior treatment. A total of 21 (0.8%) treatments were for
complicated malaria, 12 for danger signs (seven single convulsions,
three lethargy, and two vomiting), and nine for severe malaria (five
severe anemia, three multiple convulsions, and one cerebral
malaria). A total of 58 hospitalizations occurred in 34 different
children, most commonly for anemia without complicated malaria
(16), complicated malaria (14), gastrointestinal illness (seven),
respiratory tract infection (six), measles (four), and septicemia
(four). There were no significant differences in the incidence of
complicated malaria, hospitalization, diarrheal illnesses, and
respiratory tract infections between any of the intervention arms
and the no chemoprevention arm (Table 4). There was a single
death, in an 8-mo-old child randomized to no chemoprevention,
which occurred 2 d after the child was admitted for pneumonia.
Compared to the no chemoprevention arm, the prevalence of
moderate–severe anemia (hemoglobin,8 gm/dl) was significantly
higher in the SP arm (PE=270%, 95% CI, 2184% to 22%,
Figure 1. Trial profile.
1Only data that accrued until the study participant was prematurely withdrawn from the study were included in the modified intention-to-treat
analysis.
2Complete data included in the modified intention-to-treat analysis.
doi:10.1371/journal.pmed.1001689.g001
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p=0.04) and significantly lower in the DP arm (PE= 47%, 95%
CI, 1% to 72%, p=0.04) (Table 4). The mean change in
hemoglobin level from enrollment to the end of the intervention
period was higher in the TS and DP arms compared to the control
arm, but none of these comparisons reached statistical significance:
control, 0.84 gm/dl; SP, 0.82 gm/dl; TS, 0.97 gm/dl; and DP,
1.21 gm/dl. The prevalence of asymptomatic parasitemia and
gametocytemia at the time of routine blood smears was also
significantly lower in the DP arm compared to the no chemopre-
vention arm (PE= 76%, 95% CI, 59% to 86%, p,0.001, and
PE= 89%, 95% CI, 48% to 98%, p=0.006, respectively)
(Table 4).
Considering grade 3–4 adverse events regardless of relationship
to study drugs, the overall incidence and the incidence of elevated
temperature, anemia, and thrombocytopenia were significantly
lower in the DP arm, but not the SP or TS arms, compared to the
Table 1. Baseline characteristics at enrollment of study participants randomized to the intervention.
Characteristic Intervention Arm
Control (n=98) Monthly SP (n=98) Daily TS (n=99) Monthly DP (n=98)
Age in months, mean (SD) 5.4 (0.5) 5.3 (0.5) 5.4 (0.5) 5.4 (0.5)
Female gender, n (percent) 48 (49.0%) 44 (44.9%) 48 (48.5%) 52 (53.1%)
Slept under any bednet prior night, n (percent) 41 (41.8%) 43 (43.9%) 40 (40.4%) 45 (45.9%)
Slept under ITN prior night, n (percent) 27 (27.6%) 30 (30.6%) 27 (27.3%) 29 (29.6%)
Stunteda, n (percent) 10 (10.2%) 11 (11.2%) 6 (6.1%) 4 (4.1%)
Wastedb, n (percent) 4 (4.1%) 7 (7.1%) 7 (7.1%) 5 (5.1%)
Hemoglobin (gm/dl), mean (SD) 9.7 (1.4) 9.6 (1.8) 9.9 (1.5) 9.5 (1.5)
Positive thick blood smear, n (percent) 22 (22.5%) 27 (27.6%) 17 (17.2%) 28 (28.6%)
aLength-for-age z-score,22.
bWeight-for-age z-score,22.
SD, standard deviation.
doi:10.1371/journal.pmed.1001689.t001
Figure 2. Incidence of malaria over age, stratified by assigned study arm. PYAR, person-years at risk.
doi:10.1371/journal.pmed.1001689.g002
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no chemoprevention arm (Table 5). Only 19 of 424 (4.5%) grade
3–4 adverse events were classified as possibly related to study
drugs, with no significant differences between the three interven-
tion arms. Study drugs were withheld for safety concerns on 13
occasions (six TS, four SP, and three DP) in 12 different
participants; in each instance the adverse events resolved, and
study drugs were restarted. There were no significant differences in
the incidence of serious adverse events between the no chemo-
prevention and intervention arms; however, the incidence of
serious adverse events was significantly lower in the DP arm
compared to the SP arm (Table 5). ECGs were performed on 145
occasions in 19 different children on the day they received their
third dose of DP within a given month; all QTc intervals were
within normal limits.
In the year after the intervention was stopped, the incidence of
malaria in the no chemoprevention arm was 10.85 episodes per
person-year at risk (Table 6) and continued to increase with age
(Figure 2). There were no significant differences during the year
after the intervention in the incidence of malaria between any of
the groups that received chemoprevention and the no chemopre-
vention arm (Table 6). A total of 2,731 treatments were given for
malaria in the year after the intervention, including 2,696 for
incident episodes and 35 for episodes occurring within 14 d of a
prior treatment. A total of 19 (0.7%) treatments were for
complicated malaria, ten for danger signs (eight single convulsions,
one lethargy, and one vomiting), and nine for severe malaria (all
severe anemia). There were no significant differences in the
incidence of complicated malaria between any of the groups that
received prior chemopreventive therapy and the no chemopre-
vention arm (Table 6). A total of 52 hospitalizations occurred in 20
different children, most commonly for anemia without complicat-
ed malaria (29), complicated malaria (14), gastrointestinal illness
(two), respiratory tract infection (two), and convulsions without
malaria (two). The incidence of hospitalization was significantly
higher in the group that had received monthly SP compared to the
no chemoprevention arm (incidence rate ratio = 10.7, 95% CI,
2.17–53.2, p=0.004) (Table 6). There were four deaths after
chemoprevention was stopped (two in the monthly SP arm and
two in the daily TS arm); three died of severe anemia without
malaria and one died of severe malnutrition.
Discussion
We evaluated the antimalarial protective efficacy of monthly SP,
daily TS, and monthly DP in a high transmission region of
Uganda where, despite use of ITNs, the incidence of malaria in
those not receiving chemoprevention was almost seven episodes
per person-year at risk for children 6–24 mo of age and almost 11
episodes per person-year at risk for children 24–36 mo of age. This
finding underlines the fact that ITNs are not a panacea for the
control of malaria in high transmission areas. Monthly SP had no
protective efficacy against malaria and was associated with an
increased prevalence of moderate–severe anemia. Daily TS
reduced the incidence of malaria by 28% (95% CI, 1%–44%),
but offered no protection against moderate–severe anemia. In
contrast, monthly DP was highly effective, reducing the incidence
of malaria by 58% (95% CI, 45%–67%), the prevalence of
moderate–severe anemia by 47% (95% CI, 1%–72%), the
prevalence of asymptomatic parasitemia by 76% (95% CI,
59%–86%), and the prevalence of gametocytemia by 89% (95%
CI, 48%–98%). In terms of measures of impact, approximately 3
mo of chemopreventive therapy with monthly DP was needed for
each episode of malaria prevented. There were no differences
between the study arms in the incidence of malaria during the 1-y
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period after the intervention was stopped, suggesting that none of
the chemoprevention regimens had a significant impact on the
development of naturally acquired immunity.
The regular use of drugs for the prevention of malaria has been
studied in African children for over 60 y. Earlier studies focused
on continuous chemoprophylaxis, the frequent sub-therapeutic
dosing of drugs to prevent infection or its clinical manifestations.
In several randomized controlled trials chemoprophylaxis reduced
the incidence of malaria and increased hemoglobin concentrations
[11,12]. However, this strategy was never widely adopted because
of logistical constraints and the possibility that such chemopro-
phylaxis could hinder the development of antimalarial immunity
and select for drug-resistant parasites [11,12]. More recently,
attention has focused on intermittent preventive therapy (IPT), the
administration of therapeutic doses of an antimalarial drug at
predefined times regardless of an individual’s infection status, an
approach that is widely recommended for pregnant women, but of
less certain value for children [13]. Indeed, many years after the
concept of chemoprevention for high risk groups in endemic areas
was abandoned, this concept needs to be revisited, particularly in
light of the renewed interest in malaria elimination.
The most studied strategy for IPT in African children is the
administration of SP at the time of routine vaccinations, usually
three treatments in the first year of life (IPTi). In a pooled analysis
of six randomized controlled trials, IPTi with SP was associated
with a protective efficacy of 30% against malaria, 21% against
anemia, and 23% against all-cause hospitalizations [2]. However,
a subsequent study conducted from 2004 to 2008 in Tanzania
reported no protective efficacy of IPTi with SP [14]. Considering
these results and concerns regarding drug resistance, in 2010 the
WHO recommended IPTi with SP only in areas with moderate-
to-high malaria transmission and limited parasite resistance to SP,
defined as a prevalence of the pfdhps K540E mutation of #50%
[15]. Of note, following these guidelines, IPTi would not be
recommended in most of east Africa, including Uganda, where the
prevalence of the key pfdhps mutation is very high [16]. Other
drugs have also been studied for IPTi, with protective efficacies
against falciparum malaria of 38% for mefloquine in Tanzania
(although this drug was not well tolerated) [14], 26% for both SP+
artesunate (AS) and AQ+AS in Kenya [17], and 35% for SP+AQ
and 31% for SP+AS in Papua New Guinea [18].
In parts of west Africa—where malaria is seasonally restricted,
the main burden is in older children, and the prevalence of SP
resistance is low—a different approach, SMC, has been studied
[5,16]. In a number of studies, generally utilizing monthly SP+AQ
in children under 5 y of age, protective efficacies against malaria
ranged from 31% to 93% [5]. SMC has recently been
recommended as a malaria control strategy for the Sahel sub-
region by the WHO [19], and delivery by trained community
health workers has been successful in several countries [12].
However, as noted above, SMC with SP+AQ is not appropriate
for most of east Africa, and in these regions it is not clear what
alternative chemoprevention strategies are appropriate. Indeed,
the current armamentarium of drugs appropriate for chemopre-
vention is limited and dependent on compounds developed for
treatment rather than prevention. Drug development programs
Table 3. Protective efficacy against incident episodes of malaria using multivariable analyses.
Study Arm Number of Cases PYAR Incidence per PYAR Adjusted PE (95% CI)a p-Value
Control 760 109.3 6.95 Reference —
Monthly SP 725 107.8 6.73 8% (215% to 27%) 0.45
Daily TS 609 116.8 5.21 26% (6% to 41%) 0.01
Monthly DP 366 121.3 3.02 60% (49% to 69%) ,0.001
aAdjusted for household wealth index, level of education of primary caregiver, whether the child was parasitemic at enrollment, residence in village or town, type of
materials used for house construction, and nutritional status at enrollment (defined as length-for-age z-score).
PYAR, person-years at risk.
doi:10.1371/journal.pmed.1001689.t003
Figure 3. Vertical box plots of piperaquine concentrations at the time of each episode of malaria, stratified by number of days since
last dose of DP reportedly given. 10 ng/ml represents the lower limit of detection.
doi:10.1371/journal.pmed.1001689.g003
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should place a greater emphasis on drugs for chemoprevention,
considering pharmacokinetic and pharmacodynamic properties
unique to this indication.
In this study, chemoprevention interventions were tailored to an
area of east Africa with intense, year-round malaria transmission,
with regular administration from 6 to 24 mo of age. Two intensive
antifolate regimens were studied, monthly SP and daily TS,
providing much more consistent drug exposure than the
infrequent IPTi regimens previously studied in east Africa. Despite
the more intensive dosing, SP offered no significant protection
against malaria, but an excess risk of moderate–severe anemia,
and TS was associated with only 28% protective efficacy.
Although noncompliance with study drugs likely contributed to
a reduction in the protective efficacy, these results and others [16]
suggest that alternatives to antifolates are needed for malaria
chemoprevention, especially in east Africa. Indeed, in a recent
study from the same area of Uganda, over 90% of children with
malaria were infected with parasites containing five pfdhfr/pfdhps
mutations that together have been strongly correlated with
antifolate resistance [3]. The finding of an excess risk of anemia
in the monthly SP arm raises concerns that in areas of high
antifolate resistance this regimen may actually be harmful. In
studies from areas with high antifolate resistance in Tanzania,
IPTi with SP was associated with a trend towards an excess risk of
anemia in infants [14], and IPT in pregnancy with SP was
associated with an excess risk of fetal anemia [20]. In contrast,
monthly DP was safe and highly protective against malaria,
moderate–severe anemia, asymptomatic parasitemia, and game-
tocytemia. Of particular note was the lack of evidence of cardio-
toxicity despite repeated dosing with DP, confirming results of a
previous study from Thailand and contradicting current recom-
mendations of the European Regulatory Agency warning of the
risk of prolonged QTc intervals with DP [21]. These results are
not surprising given the well-demonstrated excellent treatment
efficacy and extended post-treatment prophylactic effect of DP,
which benefits from the long half-life of PQ [22]. Chemopreven-
tion with DP has previously shown promising results in two
studies. In Senegal, monthly DP during the transmission season
was well tolerated and as effective as SP+AQ for the prevention of
malaria in children, although protective efficacy could not be
estimated because of the lack of a control group [23]. In Thai
adults, the protective efficacy of DP was 98% when given monthly
Table 4. Comparative effectiveness against secondary outcomes.
Outcome Study Arm
Number of Cases or
Prevalence (Percent) PYAR
Incidence per
PYAR PE (95% CI) p-Value
Complicated malaria Control 4 138.3 0.029 Reference —
Monthly SP 6 135.5 0.044 253% (2583% to 66%) 0.58
Daily TS 6 140.1 0.043 249% (2561% to 67%) 0.60
Monthly DP 5 135.2 0.037 229% (2501% to 72%) 0.74
All-cause hospital admissions Control 8 138.5 0.058 Reference —
Monthly SP 25 135.8 0.184 2187% (2824% to 11%) 0.08
Daily TS 12 140.3 0.086 236% (2369% to 61%) 0.63
Monthly DP 13 135.4 0.096 258% (2441% to 54%) 0.47
Diarrheal illnesses Control 241 138.5 1.74 Reference —
Monthly SP 245 135.8 1.80 26% (237% to 18%) 0.65
Daily TS 271 140.3 1.93 211% (243% to 14%) 0.42
Monthly DP 275 135.4 2.03 216% (250% to 10%) 0.24
Respiratory tract infections Control 476 138.5 3.44 Reference —
Monthly SP 419 135.8 3.09 9% (211% to 26%) 0.35
Daily TS 461 140.3 3.29 4% (218% to 22%) 0.72
Monthly DP 505 135.4 3.73 28% (233% to 12%) 0.46
Moderate–severe anemia
(hemoglobin , 8 gm/dl)
Control 66/1,112 (5.9%) Reference —
Monthly SP 145/1,113 (13.0%) 270% (2184% to 22%) 0.04
Daily TS 85/1,049 (8.1%) 221% (2107% to 29%) 0.49
Monthly DP 25/899 (2.8%) 47% (1% to 72%) 0.04
Asymptomatic parasitemia Control 60/528 (11.4%) Reference —
Monthly SP 59/500 (11.8%) 23% (265% to 35%) 0.89
Daily TS 85/670 (12.7%) 210% (270% to 29%) 0.68
Monthly DP 24/849 (2.8%) 76% (59% to 86%) ,0.001
Gametocytemia Control 11/528 (2.1%) reference —
Monthly SP 18/500 (3.6%) 270% (2349% to 36%) 0.29
Daily TS 32/670 (4.8%) 2106% (2423% to 19%) 0.13
Monthly DP 2/849 (0.2%) 89% (48% to 98%) 0.006
PYAR, person-years at risk.
doi:10.1371/journal.pmed.1001689.t004
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and 86% when given every 2 mo [24]. The most important
determinant of protective efficacy in this study was the trough
plasma concentration of PQ, and it was concluded that for
chemoprevention the drug should be administered monthly.
The impact of chemoprevention on the development of
naturally acquired immunity to malaria was also of interest in
this study. Results from prior studies of the impact of chemopre-
vention on the incidence of malaria in the period after the
intervention was stopped have been mixed. In a study from
Tanzania, chemoprophylaxis with weekly pyrimethamine plus
dapsone in children 8–48 wk of age was highly efficacious, but
associated with a ‘‘rebound’’ effect leading to an increased
incidence of malaria in the year after the intervention was
stopped, suggesting that continuous chemoprophylaxis impaired
the development of naturally acquired immunity [25,26]. In
contrast, in a pooled analysis of six randomized controlled trials,
IPTi with SP was not associated with a rebound in the incidence of
malaria in the 5 mo following the intervention [2]. Indeed, in the
first study of IPTi with SP in Tanzania, SP showed the highest
protective efficacy during the intervention, and there was a
sustained reduction in the incidence of malaria in the year after the
intervention was stopped, suggesting that IPTi could actually
enhance the development of naturally acquired immunity [27]. In
a more recent study from Mozambique, chemoprevention with
monthly SP+AS between 2.5 and 4.5 mo of age or between 5.5
and 9.5 mo of age was highly effective and was associated with a
trend towards a higher risk of malaria in the second year of life
compared to children who had not received chemoprevention, but
the differences were not statistically significant [28]. In this study,
the incidence of malaria rose from 6 to 36 mo of age in the no
Table 5. Comparative safety outcomes.
Outcome Number of Events (Incidence per PYAR) by Study Arm
Control Monthly SP Daily TS Monthly DP
All grade 3–4 adverse events 169 (1.159) 202 (1.415) 135 (0.914) 87 (0.611)***
Individual grade 3–4 adverse eventsa
Elevated temperature 79 (0.542) 78 (0.546) 58 (0.393) 46 (0.323)**
Anemia 56 (0.384) 86 (0.602) 47 (0.318) 24 (0.168)**
Thrombocytopenia 18 (0.123) 17 (0.119) 9 (0.061) 5 (0.035)*
Elevated aspartate aminotransferase 7 (0.048) 8 (0.056) 6 (0.041) 3 (0.021)
Elevated alanine aminotransferase 4 (0.027) 4 (0.028) 4 (0.027) 3 (0.021)
Neutropenia 3 (0.021) 6 (0.042) 2 (0.014) 1 (0.007)
Grade 3–4 adverse events possibly related to study drugs N/A 8 (0.056) 8 (0.054) 3 (0.021)
All serious adverse events 26 (0.178) 52 (0.364) 29 (0.196) 13 (0.091)
aIncludes only those categories with at least five total events.
*p,0.05 compared to control group;
**p,0.01 compared to control group;
***p,0.001 compared to control group.
N/A, not applicable; PYAR, person-years at risk.
doi:10.1371/journal.pmed.1001689.t005
Table 6. Comparative outcomes after intervention was stopped (24–36 mo of age).
Outcome Study Arm Number of CasesPYAR Incidence per PYAR IRR (95% CI) p-Value
All incident episodes of
malaria
No chemoprevention 670 61.8 10.85 1.00 (reference) —
Prior therapy with monthly SP 689 57.5 11.98 1.11 (0.88–1.40) 0.37
Prior therapy with daily TS 678 62.2 10.90 1.01 (0.80–1.27) 0.95
Prior therapy with monthly DP 659 61.2 10.77 0.99 (0.79–1.25) 0.96
Complicated malaria No chemoprevention 4 87.4 0.046 1.00 (reference) —
Prior therapy with monthly SP 11 83.6 0.132 3.25 (0.38–27.4) 0.28
Prior therapy with daily TS 4 87.8 0.046 0.99 (0.10–9.44) 0.99
Prior therapy with monthly DP 0 86.6 0 Unable to estimate —
All-cause hospital
admissions
No chemoprevention 4 87.6 0.046 1.00 (reference) —
Prior therapy with monthly SP 38 84.0 0.452 10.7 (2.17–53.2) 0.004
Prior therapy with daily TS 8 87.9 0.091 1.99 (0.36–11.1) 0.43
Prior therapy with monthly DP 2 86.6 0.023 0.51 (0.06–4.14) 0.52
IRR, incidence rate ratio; PYAR, person-years at risk.
doi:10.1371/journal.pmed.1001689.t006
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chemoprevention arm, reaching a remarkably high level, suggest-
ing the lack of acquisition of clinically significant naturally
acquired immunity and/or a temporal increase in exposure. In
the year following the discontinuation of study drugs, the incidence
of malaria for children randomized to the three chemopreventive
regimens was similar to that of children who had not received
prior chemoprevention. The results suggest that in this high
transmission setting, the use of chemopreventive regimens with a
range of protective efficacies had little impact on the development
of naturally acquired immunity.
There were several limitations of this study. Administration of
study drugs was not directly observed. Rather, study drugs were
administered at home in a way that could be standardized across
study drug regimens. Although attempts were made to measure
compliance through the use of adherence calendars, pharmaco-
kinetic data from the DP arm suggested that compliance was much
lower than what was reported by parents/guardians. The study
also had multiple study arms with multiple primary and secondary
outcomes. Given the number of comparisons made, caution should
be taken in interpretation of significance because of the increased risk
of type-1 errors. Finally, this study was conducted in an area of high
transmission intensity and widespread antifolate resistance; therefore,
results may not be generalizable to other settings.
Our results lead to some key questions. First, considering the
long exposure to PQ after monthly dosing [10], the outstanding
efficacy demonstrated in Thailand [24], and the lack of evidence
of resistance to dihydroartemisinin or PQ in Uganda [29], why
wasn’t the preventive efficacy of DP even higher than 58%? The
most likely explanation is non-adherence to a regimen that was
administered at home without supervision, and the observed
decreasing efficacy over time might be explained by decreasing
adherence over the course of the study. In addition, pharmaco-
kinetic factors may have played a role as PQ exposure has been
shown to be lower in young children, and an increased dose
regimen may be required to achieve the same post-treatment
prophylactic effect as in older age groups [10]. Second, did
monthly DP select for parasites resistant to the components of the
drug? Studies to answer this question are underway; preliminary
results suggest that the ex vivo sensitivities of parasites isolated
from children receiving DP were not different from those of
parasites isolated from children not receiving chemoprevention (P.
J. Rosenthal, unpublished data). Further, in Burkina Faso prior
therapy with DP did not select for parasite polymorphisms selected
by the related aminoquinolines chloroquine and AQ [30],
suggesting that, despite a reported history of resistance in China
[31], PQ may not readily select for resistant parasites. Lastly, are
our results demonstrating strong protective efficacy for DP
relevant to other areas? In a 2009 malaria indicator survey,
parasite prevalence was 38% in children under 5 y in the eastern
region of Uganda, including Tororo, similar to the national
average of 43% [32]. Indeed, the most recent data from the
Malaria Atlas Project from 2010 classifies a majority of Uganda
(including Tororo) as being in the highest level of endemicity,
defined as a parasite rate of .40% among children 2–10 y of age
[33]. Thus, our results are likely representative of those to be
expected in most of Uganda. Indeed, despite well-documented
successes in reducing the burden of malaria in several African
countries [1], the burden remains remarkably high in Uganda,
and new control interventions are urgently needed [34].
The excellent efficacy of DP for the treatment of malaria in
multiple countries [22] and for chemoprevention in our high
transmission area suggest that this regimen will offer benefit in
many regions in need of improved control measures. However,
some caveats should be pointed out when considering DP for
chemoprevention. Monthly dosing of a drug given over 3 d would
pose considerable challenges in implementation and cost. For
example, the cost of a 1-y supply of study drugs for the average
size child during the intervention in this study was US$0.47 for
monthly SP, US$2.16 for daily TS, and US$12.00 for monthly
DP (based on local market prices). Additionally, widespread use
of an ACT for chemoprevention could compromise the efficacy
of the drug when used for treatment. One strategy would be the
use of ACTs with different partner drugs for prevention and
treatment, in particular utilizing drugs that select for different
resistance determinants. For example, in a recent longitudinal
randomized trial in Uganda, recent AL treatment selected for
pfmdr1 genotypes associated with decreased sensitivity to AL,
while DP selected for opposite genotypes [35]. In light of these
considerations, future studies are needed to evaluate the
preventive efficacy of DP in other areas, to maintain surveillance
for potential selection of drug-resistant parasites, and to evaluate
the role of chemoprevention in the context of other available
malaria control interventions such as the scale-up of ITNs and
use of indoor residual spraying of insecticides. In addition, there
are numerous programmatic barriers that will need to be
addressed such as developing appropriate delivery systems (e.g.,
use of community health workers), ensuring compliance and
proper dosing, and, perhaps most challenging, providing
adequate funding in an environment where resources are already
scarce.
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Editors’ Summary
Background. Malaria is a parasitic disease that kills more
than 600,000 people (mainly young children living in sub-
Saharan Africa) every year. Malaria parasites, which are
transmitted to people through the bites of night-flying
mosquitoes, cause a characteristic fever that needs to be
treated promptly with antimalarial drugs to prevent anemia
and organ damage. Prompt treatment also helps to reduce
malaria transmission and is a component of the Global
Malaria Action Plan, which aims to control and eventually
eliminate malaria. Other components of this plan include the
provision of insecticide-treated bednets for people to sleep
under to avoid mosquito bites and indoor residual spraying
with insecticides. Widespread deployment of these preven-
tative tools and the increased availability of effective
antimalarial drugs have greatly reduced malaria-related
deaths worldwide over the past decade, but new strategies
are still urgently needed to reduce the burden of malaria
among those most at risk—young children living in Africa.
Why Was This Study Done? One promising strategy for
the prevention of malaria in African children is the use of
antimalarial drugs to prevent rather than treat malaria. In
trials, giving infants sulfadoxine-pyrimethamine (SP) along-
side routine vaccinations, for example, reduced the incidence
of malaria (the number of new cases in the population in a
year) by about 30% during the first year of life (a protective
efficacy of 30%). However, the optimal chemoprevention
drug and dosing strategy for children living in African
regions where there is year-round transmission of malaria
and where resistance to antimalarial drugs is common
remains unclear. Here, the researchers undertake an open-
label randomized controlled trial (RCT) of chemoprevention
in infants in the Tororo District of eastern Uganda, an area
with intense year-round malaria transmission. RCTs compare
outcomes in groups of people chosen to receive different
interventions through the play of chance; in open-label RCTs,
both the researchers and the participants know which
treatment is being administered.
What Did the Researchers Do and Find? The researchers
assigned 393 six-month-old infants to receive no chemopre-
vention, monthly SP, daily trimethoprim-sulfamethoxazole
(TS), or monthly dihydroartemisinin-piperaquine (DP) until
they were 24 months old. SP and TS block the production of
folic acid, which malaria needs for survival, whereas DP is a
newer artemisinin-based combination therapy (ACT). All the
drugs were given at home without supervision, and
caregivers were asked to bring their children to a study
clinic whenever they were ill. During the intervention, the
incidence of malaria was 6.95 episodes per person-year at
risk in the no chemoprevention arm but only three episodes
per person-year at risk in the DP arm. That is, the protective
efficacy of DP was 58%. By contrast, the protective efficacies
of TS and SP were 28% and 7%, respectively. However, for SP
the protective efficacy was not statistically different com-
pared to the no chemoprevention arm. Notably, piperaquine
levels on the day that malaria was diagnosed were below the
detection limit in half of the malaria episodes in the DP arm,
which suggests that a complete dose of DP had not been
given to the infant in the previous month, despite caregivers
reporting that they had administered virtually all the
assigned doses. Finally, the incidence of serious adverse
events was similar in all the study arms during the
intervention, as was the incidence of malaria during the
year after the intervention, which suggests that the
chemoprevention strategies did not affect the development
of naturally acquired immunity.
What Do These Findings Mean? These findings show
that, for children living in an area of intense malaria
transmission, monthly DP was the most efficacious strategy
for malaria chemoprevention but that adherence to the
strategy may have been a problem. These findings also
suggest that monthly SP and daily TS may not be
appropriate chemoprevention strategies in areas of high
transmission intensity, particularly those where resistance to
antifolate drugs is common. The accuracy of these findings
may be affected by drug administration being self-reported
and by the number of comparisons included in the trial,
which may have increased the risk of false-positive results.
Moreover, the results of this trial may not be generalizable to
other regions of sub-Saharan Africa. Overall, however, these
results suggest that monthly DP is a strategy worth
considering in regions in need of improved malaria control
measures, with the important caveat that widespread ACT
use for chemoprevention could compromise the efficacy of
ACT when used for treatment.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001689.
N Information is available from the World Health Organiza-
tion on malaria (in several languages), including informa-
tion on malaria chemoprevention; the World Malaria
Report 2013 provides details of the current global malaria
situation, including information on malaria in Uganda
N The US Centers for Disease Control and Prevention provide
information on malaria, including information on ways to
reduce malaria cases and deaths; it also provides a
selection of personal stories about malaria, including a
story about malaria in a child in Africa
N Information is available from the Roll Back Malaria
Partnership on the global control of malaria and on the
Global Malaria Action Plan (in English and French); its
website includes fact sheets about malaria in Africa and
about children and malaria
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
N More information about this trial is available
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